Natera (NASDAQ:NTRA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Natera (NASDAQ:NTRA) had its price target hoisted by Canaccord Genuity Group from $150.00 to $165.00 in a research note published on Wednesday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

NTRA has been the topic of a number of other research reports. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. BTIG Research boosted their price objective on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, August 9th. UBS Group decreased their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Robert W. Baird boosted their price objective on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Stephens restated an “overweight” rating and issued a $125.00 price objective on shares of Natera in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average target price of $135.06.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $160.97 on Wednesday. The stock has a market cap of $19.91 billion, a PE ratio of -91.46 and a beta of 1.53. The company’s fifty day moving average is $126.04 and its 200 day moving average is $114.84. Natera has a 52 week low of $49.97 and a 52 week high of $167.79. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.88%. The firm’s revenue was up 63.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.95) EPS. Research analysts anticipate that Natera will post -1.96 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 5,024 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the sale, the chief executive officer now owns 195,686 shares of the company’s stock, valued at $25,141,737.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Steven Leonard Chapman sold 5,024 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $128.48, for a total value of $645,483.52. Following the transaction, the chief executive officer now owns 195,686 shares in the company, valued at approximately $25,141,737.28. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Solomon Moshkevich sold 1,196 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $118.21, for a total transaction of $141,379.16. Following the completion of the transaction, the insider now owns 110,695 shares in the company, valued at approximately $13,085,255.95. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,881 shares of company stock valued at $3,733,983 over the last quarter. Corporate insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC lifted its stake in shares of Natera by 1,073.1% in the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after buying an additional 60,127 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Natera by 15.1% in the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock worth $6,810,000 after buying an additional 9,781 shares in the last quarter. Natixis bought a new position in shares of Natera in the first quarter worth approximately $758,000. Chartwell Investment Partners LLC raised its holdings in shares of Natera by 37.9% during the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after purchasing an additional 11,362 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft purchased a new position in shares of Natera during the second quarter valued at approximately $478,000. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.